EBMT 2022 | Oral manifestations of immune-related adverse events in checkpoint inhibitor treatment

Nathaniel Treister • 22 Mar 2022

EBMT 2022

General

Nathaniel Simon Treister, DMD, DMSc, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, MA explains the immune-related adverse events after checkpoint inhibitor treatment, which could affect the mouth. Timing can be variable but oral manifestations normally appear abruptly, reflecting characteristics of a variety of diagnosis-related conditions including chronic graft-versus-host disease (GvHD). These manifestations may not be unique to a particular condition, such as non-specific inflammation or ulcerations in large areas of the oral cavity. In most cases the diagnosis is clinical and the management can usually be performed with topical corticosteroids or tacrolimus and, in some cases, with systemic therapy. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.